Most Read Articles
Jairia Dela Cruz, 25 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
one month ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
Pearl Toh, 6 days ago
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 22 hours ago
Patterns of sleeping behaviour are associated with macronutrient intake among women of reproductive age, and this association varies based on sleep duration and the presence or absence of sleep-related symptoms, according to a study.

Add-on phentermine enhances weight loss in obese teens

5 months ago

Short-term use of the norepinephrine reuptake inhibitor phentermine in addition to standard of care (SOC) lifestyle modification therapy may lead to greater weight loss in adolescents with obesity compared with SOC alone, according to a study.

Researchers examined the medical records of obese adolescents treated in a paediatric weight management clinic to examine the effect of using phentermine as an add-on to SOC lifestyle modification therapy. The population comprised 25 patients (mean age 16.1 years; mean BMI, 41.2 kgm−2) receiving phentermine plus SOC and 274 patients (mean age 14.9 years; mean BMI, 38.1 kgm−2) receiving only SOC.

The patients were evaluated at 1, 3 and 6 months using generalized estimated equations to determine the differences between the two treatment interventions. Age, sex and BMI were included in the analysis as potential confounders. Robust variance standard error estimates were used to calculate confidence intervals and p-values.

Results showed that the percent change in BMI overall was greater in the phentermine group than in the SOC-only group. The respective changes at 1, 3 and 6 months were −1.6 percent (95 percent CI, −2.6 to −0.6; p=0.001), −2.9 percent (−4.5 to −1.4; p<0.001) and −4.1 percent (−7.1 to −1.0; p=0.009).

There were no significant intergroup differences in systolic or diastolic blood pressure. However, heart rate was higher in patients receiving phentermine plus SOC at all time points.

Given the present data and phentermine’s long track record without major safety concerns, the norepinephrine reuptake inhibitor is a viable treatment option for paediatric obesity.

Further investigation should be conducted regarding the efficacy of phentermine as a monotherapy or in combination with other medications in paediatric obesity, researchers said. Future clinical trials should explore potential mechanisms of action and predictors of response, as well as include additional endpoints such as changes in cardiometabolic risk factors, quality of life and noninvasive vascular measurements.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 25 days ago
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
one month ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
Pearl Toh, 6 days ago
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 22 hours ago
Patterns of sleeping behaviour are associated with macronutrient intake among women of reproductive age, and this association varies based on sleep duration and the presence or absence of sleep-related symptoms, according to a study.